Señales en vivo de 6541.TW | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 01:30):

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States...

Stats
Volumen de hoy	419 107
Volumen promedio	345 448
Capitalización de mercado	7.20B
EPS	TWD0 ( 2024-03-14 )
Próxima fecha de ganancias	( TWD0 ) 2024-05-07
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-2.78
ATR14	TWD0.0870 (0.19%)

Volumen Correlación

Largo: 0.17 (neutral)

Corto: 0.99 (very strong)

Signal:(45.463) Expect same movement, but be aware

Tanvex BioPharma, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tanvex BioPharma, Inc. Correlación - Moneda/Commodity

-0.06
( neutral )

-0.16
( neutral )

0.00
( neutral )

-0.30
( neutral )

-0.17
( neutral )

0.03
( neutral )

Tanvex BioPharma, Inc. Finanzas

Annual	2023
Ingresos:	TWD61.41M
Beneficio Bruto:	TWD-265.13M (-431.73 %)
EPS:	TWD-16.42

FY	2023
Ingresos:	TWD61.41M
Beneficio Bruto:	TWD-265.13M (-431.73 %)
EPS:	TWD-16.42

FY	2022
Ingresos:	TWD22.40M
Beneficio Bruto:	TWD-19.35M (-86.36 %)
EPS:	TWD-13.55

FY	2021
Ingresos:	TWD5.41M
Beneficio Bruto:	TWD3.55M (65.67 %)
EPS:	TWD-5.70

Financial Reports:

No articles found.

Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Actualizaciones en tiempo real para Tanvex BioPharma, Inc. [6541.TW]

Upcoming Earnings Alert